← Back to Clinical Trials
Recruiting NCT03378739

NCT03378739 Inova Cardiogenic Shock Registry (INOVA SHOCK)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03378739
Status Recruiting
Phase
Sponsor Inova Health Care Services
Condition Cardiogenic Shock
Study Type OBSERVATIONAL
Enrollment 3,000 participants
Start Date 2018-01-01
Primary Completion 2099-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 85 Years
Study Type OBSERVATIONAL
Interventions
Cardiogenic Shock team activation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 3,000 participants in total. It began in 2018-01-01 with a primary completion date of 2099-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To collect retrospective clinical outcomes related to acute decompensated heart failure cardiogenic shock, acute myocardial infarction cardiogenic shock and compare current versus historical survival rates. To collect Inova Heart and Vascular Institute (IHVI) site specific outcomes before and after initiation of the Cardiogenic Shock team on January 1, 2017. To collect outcomes related to implementation of mechanical circulatory support versus no circulatory intervention and type of intervention (extracorporeal membrane oxygenation (ECMO) versus intracorporeal axial-flow (Impella). • Assess survival at three time points.

Eligibility Criteria

Inclusion Criteria: -Patients at the IHVI with documented Cardiogenic Shock team intervention for acute decompensated heart failure cardiogenic shock, or acute myocardial infarction cardiogenic shock. Exclusion Criteria: -Patients under the age of 18 will be excluded.

Contact & Investigator

Central Contact

Bhruga Shah

✉ bhruga.shah@inova.org

📞 703-776-2828

Principal Investigator

Vanessa Blumer, MD

PRINCIPAL INVESTIGATOR

Inova Health Care Services

Frequently Asked Questions

Who can join the NCT03378739 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Cardiogenic Shock. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03378739 currently recruiting?

Yes, NCT03378739 is actively recruiting participants. Contact the research team at bhruga.shah@inova.org for enrollment information.

Where is the NCT03378739 trial being conducted?

This trial is being conducted at Falls Church, United States.

Who is sponsoring the NCT03378739 clinical trial?

NCT03378739 is sponsored by Inova Health Care Services. The principal investigator is Vanessa Blumer, MD at Inova Health Care Services. The trial plans to enroll 3,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology